Description
PBMCs from systemic lupus erythematosus (SLE) donors, isolated from leukopak material under cGMP-aligned conditions. Sourced from OrganaBio’s qualified, recallable donor pool with 14-marker infectious disease screening per 21 CFR 1271 and high-resolution NGS HLA typing. OrganaBio reports an average 99.1% PBMC viability across more than 2,500 clinical samples. Best fit: autoimmune drug screening, biomarker discovery, and disease-state immune dysregulation studies.
LeukoPAC-D-PBMC – Disease-State Cryopreserved Peripheral Blood Mononuclear Cells
LeukoPAC-D-PBMC delivers cryopreserved peripheral blood mononuclear cells from donors with documented disease conditions, collected under IRB-approved protocols. Disease-state PBMCs are essential for cell therapy development because manufacturing processes and assays optimized using healthy donor cells frequently fail to translate to cells from patients in the target population.
Why Disease-State PBMCs
Patients eligible for cell therapies have often been treated with multiple rounds of chemotherapy or other interventions, which can compromise T cell functionality and shift cellular phenotypes in ways that healthy donor controls do not capture. Process development on disease-state PBMCs allows manufacturing teams and assay developers to validate workflows against material that reflects the immune biology of the patient population they intend to treat.
Available Indications
Disease-state PBMCs are available across autoimmune indications (including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, type 1 diabetes, Crohn’s disease, psoriasis, and celiac), oncology (liquid and solid tumors), and chronic inflammatory conditions (including COPD and osteoarthritis), among others. Contact the scientific team to confirm availability for your specific indication.
Documentation
Each sample is supported by comprehensive documentation including disease history, treatment background, inclusion and exclusion criteria compliance, and demographic profiles. Every lot ships with a Certificate of Analysis. Donors are enrolled under IRB-approved protocols with verified clinical diagnosis.
Configuration
Standard configuration: 1.0×10⁷ cells per vial, cryopreserved, stored at <−150°C in liquid nitrogen vapor phase. Custom cell counts, fresh format, and specific donor criteria available on request. Cells are for preclinical research use only and not for use in humans.
For background on disease-state donor samples in cell therapy development, see Why Disease-State Donor Samples Are Essential for Cell Therapy Development.
Frequently Asked Questions
What are SLE/Lupus PBMCs used for?
PBMCs from SLE/Lupus donors are used for autoimmune drug screening, biomarker discovery, immune-cell-therapy research targeting autoimmune populations, and disease-state-vs-healthy comparative immunology studies.
What viability can I expect for cryopreserved SLE PBMCs?
OrganaBio reports an average 99.1% post-thaw PBMC viability across more than 2,500 clinical samples processed via its CPC Services workflow.
Are SLE PBMC donors recallable?
Yes. OrganaBio maintains a recallable donor pool. Disease-state donors can be re-collected for longitudinal studies under the same characterization profile.
What HLA typing is provided for SLE PBMC donors?
High-resolution NGS HLA typing across HLA-A, B, C, DR, DQ, and DP is performed on every donor. KIR genotyping is available for NK-relevant programs.
Are SLE PBMCs available at cGMP grade?
Yes. The same SLE donor pool serves both RUO and cGMP grades under one quality system. Programs moving from preclinical research to clinical material do not requalify donors.
